NYU Langone medical oncologist Dr. David Wise discusses immunotherapy and genetically targeted therapies in prostate cancer treatment.
Learn more about Dr. Wise: https://nyulangone.org/doctors/1336438258/david-r-wise
Learn more about NYU Langone’s Perlmutter Cancer Center: http://nyulangone.org/locations/perlmutter-cancer-center
Thanks! Share it with your friends!
NYU Langone medical oncologist Dr. David Wise discusses immunotherapy and genetically targeted therapies in prostate cancer treatment.
Learn more about Dr. Wise: https://nyulangone.org/doctors/1336438258/david-r-wise
Learn more about NYU Langone’s Perlmutter Cancer Center: http://nyulangone.org/locations/perlmutter-cancer-center
You must be logged in to post a comment.
![Chronic Pain Attack [Oh my God, babe??] [Public Place] [Let's Get You Home]](https://i.ytimg.com/vi/3UPe96zlzpk/hqdefault_live.jpg "Chronic Pain Attack [Oh my God, babe??] [Public Place] [Let's Get You Home]")
){kind=link}
Could a patient whose prostate cancer has spread to bones still receive benefit from the new hormonal treatment or possibly even (with correct cancer type match) the immunotherapy?